Evidence for control of nitric oxide synthesis by intracellular transforming growth factor-β1 in tumor cells: Implications for tumor development

American Journal of Pathology

Volumn 154, Issue 6, 1999, Pages 1867-1876

  Lagadec, Patricia ^a   Raynal, Stéphane ^b   Lieubeau, Blandine ^c   Onier, Nathalie ^a   Arnould́, Laurent ^d   Saint Giorgio, Valérie ^a   Lawrence, David A ^b   Jeannin, Jean François ^a  

^a PSL RESEARCH UNIVERSITY   (France)

^b CNRS   (France)

^c INSTITUT DE BIOLOGIE   (France)

^d GF Leclerc Regional Anticancer Centre   (France)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID A; MESSENGER RNA; NITRIC OXIDE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CARCINOMATOUS PERITONITIS; COLON CARCINOMA; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; IMMUNOBLOTTING; IMMUNOHISTOLOGY; IMMUNOTHERAPY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0033022858     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65444-2     Document Type: Article

References (41)

1. Ebert EC, Roberts AJ, Devereux D, Nagase H: Selective immunosuppressive action of a cofactor produced by colon cancer cells. Cancer Res 1990, 50:6158-6161
2. Grégoire M, Garrigue L, Blottière HM, Denis MG, Meflah K: Possible involvement of TGF-β1 in the distinct tumorigenic properties of two rat colon carcinoma clones. Invasion Metastasis 1992, 12:185-196
3. Lagadec P, Reveneau S, Lejeune P, Pinard D, Borman T, Bauer J, Jeannin JF: Immunomodulator OM 163-induced reversal of tumor-mediated immunosuppression and down-regulation of TGF-β1 in vivo. J Pharmacol Exp Ther 1996, 278:926-933
4. Tsushima H, Kawata S, Tamura S, Ito N, Shirai Y, Kiso S, Imai Y, Shimomukai H, Nomura Y, Matsuda Y, Matsuzawa Y: High levels of transforming growth factor-β1 in patients with colorectal cancer: association with disease progression. Gastroenterology 1996, 110:375-382
5. Weller M, Fontana A: The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-β, T cell apoptosis, and the immune privilege of the brain. Brain Res Rev 1995, 21:128-151
6. Lahm H, Odartchenko N: Role of transforming growth factor-β in colo-rectal cancer. Growth Factors 1993, 9:1-9
7. Lieubeau B, Garrigue L, Barbieux I, Meflah K, Grégoire M: The role of transforming growth factor β1 in the fibroblastic reaction associated with rat colorectal tumor development. Cancer Res 1994, 54:6526-6532
8. Wojtowicz-Praga S: Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother 1997, 20:165-177
9. Alleva DG, Burger CJ, Elgert KD: Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-α production. Role of tumor-derived IL-10, TGF-p, and prostaglandin E2. J Immunol 1994, 153:1674-1686
10. Ito N, Kawata S, Tamura S, Takaishi K, Shirai Y, Kiso S, Yabuuchi I, Matsuda Y, Wisioka M, Tarui S: Elevated levels of transforming growth factor β messenger RNA and its polypeptide in human hepatocellular carcinoma. Cancer Res 1996, 51:4080-4083
11. Hausmann E, Hao SY, Pace J, Parmely M: Transforming growth factor-β1 and gamma-interferon provide opposing signals to lipopolysaccharide-activated mouse macrophage. Infect Immun 1994, 62: 3625-3632
12. Vodovotz Y, Bogdan C, Paik J, Xie QW, Nathan C: Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor-β1. J Exp Med 1993, 178:605-613
13. Hibbs JB, Taintor RR, Vavrin Z: Macrophage cytotoxicity: role for L-arginine deiminase and iminonitrogen oxidation to nitrite. Science 1987, 235:473-476
14. Farias-Eisner R, Sherman MP, Aeberhard E, Chaudhuri G: Nitric oxide is an important mediator for tumoricidal activity in vivo. Proc Natl Acad Sci USA 1994, 91:9407-9411
15. Lejeune P, Lagadec P, Onier N, Pinard D, Oshima H, Jeannin JF: Nitric oxide involvement in tumor-induced immunosuppression. J Immunol 1994, 152:5077-5083
16. Jenkins DC, Charles IG, Baylis SA, Lelchuk R, Ranomski MW, Moncada S: Human colon cancer cell lines show a diverse pattern of nitric oxide synthase gene expression and nitric oxide generation. Br J Cancer 1994, 70:847-849
17. Xie KP, Dong ZY, Fidler IJ: Activation of nitric oxide synthase gene for inhibition of cancer metastasis. J Leukoc Biol 1996, 59:797-803
18. Xie K, Huang S, Dong Z, Juang SH, Wang Y, Fidler IJ: Destruction of bystander cells by tumor cells transfected with inducible nitric oxide (NO) synthase gene. J Natl Cancer Inst 1997, 89:421-427
19. Ding AH, Nathan CF, Stuehr DJ: Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J Immunol 1988, 141:2407-2412
20. Onier-Cherix N, Hilpert S, Reveneau S, Arnould L, Saint-Giorgio V, Exbrayat JM, Jeannin JF: Expression of inducible nitric oxide synthase in tumors in relation with their regression induced by a lipid A in rats. Int J Cancer 1999, 81:755-760
21. Martin F, Caignard A, Jeannin JF, Leclerc A, Martin MS: Selection by trypsin of two sublines of rat colon cancer cells forming progressive or regressive tumors. Int J Cancer 1983, 32:623-627
22. Juillerat-Jeanneret L, Aguzzi A, Wiestler OD, Darekar F, Janzer RC: Dexamethasone selectively regulates the activity of enzymatic markers of cerebral endothelial cell lines. In Vitro Cell Dev Biol Anim 1992, 28A:537-543
23. Oshima H, Brouet IM, Brandaletova T, Adachi H, Oguchi S, Iida S, Kurashima Y, Morishita Y, Sugimura T, Esumi H: Polyclonal antibody against an inducible form of nitric oxide synthase from the liver of rats treated with propionibacterium acnes and lipopolysaccharides. Biochem Biophys Res Comm 1992, 187:1291-1297
24. Raynal S, Lawrence DA: Differential effects of transforming growth factor-β1 on protein levels of p21 WAF and cdk-2 and on cdk-2 kinase activity in human RD and CCL64 mink lung cells. Int J Oncol 1995, 7:337-341
25. Franzén P, ten Dijke P, Ichijo H, Yamashita H, Schulz P, Heldin CH, Miyazono K: Cloning of a TGF-β type I receptor that forms a heterodimeric complex with the TGF-β type II receptor. Cell 1993, 75: 681-692
26. 15N]nitrate in biological fluids. Anal Biochem 1982, 126:131-138
27. Gilbert RS, Herschman HR: Transforming growth factor beta differentially modulates the inducible nitric oxide synthase gene in distinct cell types. Biomed Biophys Res Comm 1993, 195:380-384
28. Vodovotz Y, Letterio JJ, Geiser AG, Chester L, Roberts AB, Sparrow J: Control of nitric oxide production by endogenous TGF-β1 and systemic nitric oxide in retinal pigment epithelial cells and peritoneal macrophages. J Leukoc Biol 1996, 60:261-270
29. Vodovotz Y, Geiser AG, Chesler L, Letterio JJ, Cambell A, Scott Lucia M, Sporn MB, Roberts AB: Spontaneously increased production of nitric oxide and aberrant expression of the inducible nitric oxide synthase in vivo in the transforming growth factor-β1 null mouse. J Exp Med 1996, 183:2337-2342
30. Craven PA, Studer RK, Felder J, Phillips S, DeRubertis FR: Nitric oxide inhibition of transforming growth factor-beta and collagen synthesis in mesangial cells. Diabetes 1997, 46:671-681
31. Markowitz SD, Wang KJ, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, Brattain M, Willson JKV: Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 1995, 268:1336-1338
32. Mazars P, Barboule N, Baldin V, Vidal S, Ducommun B, Valette A: Effects of TGF-β1 (transforming growth factor-β1 ) on the cell cycle regulation of human breast adenocarcinoma (MCF-7) cells. FEBS Lett 1995, 362:295-300
33. Chen RH, Ebner R, Derynck R: Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-β activities. Science 1993, 260:1335-1338
34. Caver TE, O'Sullivan FX, Gold LI, Gresham HD: intracellular demonstration of active TGF-β1 in B cells and plasma cells of autoimmune mice. J Clin Invest 1996, 98:2496-2506
35. Smith MR, Muegge K, Keller JR, Kung HS, Young HA, Durum SK: Direct evidence for an intracellular role for IFN-γ. Microinjection of human IFN-γ induces la expression on murine macrophages. J Immunol 1990, 144:1777-1782
36. Johnson HM, Torres BA, Green MM, Szente BE, Siler KI, Larkin J, Subramaniam PS: Cytokine-receptor complexes as chaperones for translocation of signal transducers. Biochem Biophys Res Comm 1998, 244:607-614
37. Weitzmann MN, Savage N: Nuclear internalisation and DNA binding activities of interleukin-1, interleukin-1 receptor and interleukin-1/receptor complexes. Biochem Biophys Res Comm 1992, 187:1166-1171
38. Zhan X, Hu X, Friedman S, Maciag T: Analysis of endogenous and exogenous nuclear translocation of fibroblast growth factor-1 in NIH 3T3 cells. Biochem Biophys Res Comm 1992, 188:982-991
39. Zhu Y, Richardson JA, Parada LF, Graff JM: Smad 3 mutant mice develop metastatic colorectal cancer. Cell 1998, 94:703-714
40. Goldring C, Narayanan R, Lagadec P, Jeannin JF: Transcriptional inhibition of the inducible nitric oxide synthase gene by competitive binding of NF-KB/REL proteins. Biochem Biophys Res Commun 1995, 209:73-79
41. Arsura M, Wu M, Sonenshein GE: TGF-β1 inhibits NF-KB/REL activity inducing apoptosis of B cells: transcriptional activation of IKBα. Immunity 1996, 5:31-40